UVD Robots Deploys Largest Fleet of Autonomous Disinfection Robots to a U.S. School District
26.3.2021 16:15:00 EET | Business Wire | Press release
Blue Ocean Robotics, the manufacturer of the autonomous disinfecting robot UVD Robots equipped with UV-C light, has been selected by Gallup McKinley County Schools (GMCS) in New Mexico to supply 37 UVD Robots to the districts’ schools to help fight the Coronavirus and other infectious diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210326005133/en/
Students from GMCS’ Twin Lakes School participated in a naming contest for the robot to help with socialization and morale. The school’s robot will now be known as Mr. Fox. UVD Robots were originally developed to fight Hospital Acquired Infections (HAI’s) and are now deployed in more than 60 countries worldwide in the healthcare sector, the hospitality industry, office complexes and educational facilities, meeting new and heightened expectations for safety and cleanliness. (Photo: Business Wire)
“COVID has taken an extraordinary toll on our community. The safety of our students and staff, developing a plan to bring them all back to school as safely as possible is our primary concern,” said Gallup McKinley Superintendent Michael Hyatt. “We wanted a larger, longer-term disinfection solution, adding a layer of protection that would disinfect surfaces and the air in our buildings and help fight COVID, colds, flu and infectious diseases for years to come.”
GMCS covers a community with many rural areas facing infrastructure issues that make virtual learning a challenge, approximately 1,500 students have no internet at home. The district also educates many special education students who learn better in the classroom.
“Unlike stationary disinfection robots, the UVD Robot is a fully autonomous robot. It integrates UV-C light to disinfect against viruses and bacteria on surfaces and the air, killing 99.99 percent of microorganisms within approximately 10 minutes in every room it disinfects,” said Claus Risager, CEO, Blue Ocean Robotics.
“We selected UVD Robots after rigorous review of numerous disinfecting robots,” said Hyatt. “UVD Robots delivered on all of our requirements including technical excellence, maturity and track record, quality of deployment, technical support and maintenance, and overall value.”
“We are excited to announce, what we believe is the largest deployment of autonomous disinfection robots in any U.S. school district,” said Per Juul Nielsen, CEO, UVD Robots. “We are honored to work with GMCS to go beyond COVID, bringing hospital-grade disinfection to the school district.”
About
UVD Robots is part of one of the world's leading groups in development of service robots, Blue Ocean Robotics, that includes brands GoBe Robots and PTR Robots. Blue Ocean Robotics is headquartered in Denmark and was recently included on Fast Company’s Top 10 of ‘Most Innovative Robotics Companies 2021.’
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005133/en/
Contact information
Camilla Almind Knudsen, Blue Ocean Robotics
+45 61 10 02 74
cak@blue-ocean-robotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom